Literature DB >> 1341325

Abnormal regulation of the myc gene in myeloid leukemia.

V Gopal1, P Kadam, H Preisler, B Hulette, Y Q Li, P Steele, J Freeman, S Banavali.   

Abstract

To study the regulation of expression of the myc protooncogene, cells from normal individuals and patients with acute myelogenous leukemia (AML), and chronic phase and blastic crisis of chronic myeloid leukemia (CML) cells were put in overnight culture in the presence or absence of fetal calf serum. Myc expression in normal marrow cells and chronic phase CML cells fell after culture in vitro. In contrast, myc expression was maintained or increased in a majority of the AML and blastic crisis CML specimens. These data demonstrate that the regulation of myc expression is disordered in many AML and blastic crisis specimens but not in chronic phase CML cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1341325     DOI: 10.1007/bf02987745

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  8 in total

1.  Potentiation of growth factor activity by exogenous c-myc expression.

Authors:  V Sorrentino; V Drozdoff; M D McKinney; L Zeitz; E Fleissner
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

2.  Biological activities of v-myc and rearranged c-myc oncogenes in rat fibroblast cells in culture.

Authors:  E Mougneau; L Lemieux; M Rassoulzadegan; F Cuzin
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

3.  Cell-cycle control of c-myc but not c-ras expression is lost following chemical transformation.

Authors:  J Campisi; H E Gray; A B Pardee; M Dean; G E Sonenshein
Journal:  Cell       Date:  1984-02       Impact factor: 41.582

4.  Avian myelocytomatosis virus immortalizes differentiated quail chondrocytes.

Authors:  E Gionti; G Pontarelli; R Cancedda
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

5.  Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: a review of three consecutive trials of the treatment of poor prognosis patients.

Authors:  H Preisler; A Raza; R Larson; J Goldberg; G Tricot; M Carey; C Kukla
Journal:  Leuk Res       Date:  1991       Impact factor: 3.156

6.  Production of hepatocellular carcinoma by oval cells: cell cycle expression of c-myc and p53 at different stages of oval cell transformation.

Authors:  L Braun; R Mikumo; N Fausto
Journal:  Cancer Res       Date:  1989-03-15       Impact factor: 12.701

7.  Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product.

Authors:  G I Evan; G K Lewis; G Ramsay; J M Bishop
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

8.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

  8 in total
  3 in total

1.  A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.

Authors:  Mario Notari; Paolo Neviani; Ramasamy Santhanam; Bradley W Blaser; Ji-Suk Chang; Annamaria Galietta; Anne E Willis; Denis C Roy; Michael A Caligiuri; Guido Marcucci; Danilo Perrotti
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

Review 2.  BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention.

Authors:  Danilo Perrotti; Jason G Harb
Journal:  Leuk Lymphoma       Date:  2011-01-11

3.  BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.

Authors:  Nitesh Sharma; Vera Magistroni; Rocco Piazza; Stefania Citterio; Caterina Mezzatesta; Praveen Khandelwal; Alessandra Pirola; Carlo Gambacorti-Passerini
Journal:  Mol Cancer       Date:  2015-07-16       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.